business

Jon Keegan9/30/24

Ford takes aim at Tesla, offering free EV chargers and home installation to buyers

In a major move to court car shoppers who are leery of EVs, Ford — the number two EV seller behind Tesla— announced a new program to provide free Level 2 home chargers and installation to new Ford EV car buyers, an incentive worth several thousands of dollars. The program could help Ford eat away at Tesla’s dominant share of the EV market in the US.

“We have learned just how important home charging is to overall electric vehicle adoption in the U.S. Nearly 90% of shoppers say they would be more likely to buy an electric vehicle if they knew they could charge at home,” wrote Ford CEO Jim Farley announcing the new program, which is called the “Ford Power Promise”.

The offer is good for any purchase or lease of a Ford F-150 Lightning, Mustang Mach-E, or E-Transit Cargo Van starting October 1, 2024 and runs through the end of the year.

Ford recently pulled back from its ambitious EV plans, delaying new EV models and ramping up production of more popular hybrid models.

Ford F-150 Lightning, Mustang Mach-E Get Free Home Charger And Installation

Ford F-150 Lightning, Mustang Mach-E Get Free Home Charger And Installation

“We have learned just how important home charging is to overall electric vehicle adoption in the U.S. Nearly 90% of shoppers say they would be more likely to buy an electric vehicle if they knew they could charge at home,” wrote Ford CEO Jim Farley announcing the new program, which is called the “Ford Power Promise”.

The offer is good for any purchase or lease of a Ford F-150 Lightning, Mustang Mach-E, or E-Transit Cargo Van starting October 1, 2024 and runs through the end of the year.

Ford recently pulled back from its ambitious EV plans, delaying new EV models and ramping up production of more popular hybrid models.

More Business

See all Business

Claire Yubin Oh

in this econemy?

Van Leeuwen, America’s fastest-growing dessert chain, is looking to expand abroad

The boutique ice cream chain is looking to open at least 300 new shops in South Korea over the next decade.

Van Leeuwen Ice Cream Truck Los Angeles

J. Edward Moreno

Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s.

Hims & Hers Health CEO Andrew Dudum

business

Nate Becker2/7/26

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims & Hers Comms on X

Hims & Hers Comms on X: "Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us" / X

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

J. Edward Moreno2/6/26

Max Knoblauch2/6/26

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.

©2026 Sherwood Media, LLC